Boehringer Ingelheim snags second client for its China CMO operation

Just days after announcing its inaugural deal, Boehringer Ingelheim's contract manufacturing operation in China has picked up a second client. The German drugmaker last week said it has an agreement to manufacture a monoclonal antibody candidate for Shanghai-based biotech ZAI Lab. This deal comes shortly after Boehringer said it has won its first client with a deal to manufacture immuno-oncology drugs for Beijing-based BeiGene, once it completes construction of a €35 million ($44.9 million) plant it is building in Shanghai. The facility, which the company is using to do contract manufacturing in China, is slated to be operational in Q1 2017 and to have about 65 employees. Release (PDF) | More

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

Roche's global manufacturing leader Pierre-Alain Ruffieux will take the reins and oversee the Moderna COVID-19 vaccine collaboration.